NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

July 2010 Marketed Drug Updates and Additions

Brand Name

Generic Name

Other Designation

Lupron, Lupron Depot, Leuplin (Japan), Lucrin, Enantone (Germany), Prostap

Leuprolide acetate, leuprorelin

TAP-144SR

Abraxane

Nanoparticle albumin-bound (nab) paclitaxel, paclitaxel albumin bound (PAB)

ABI-007

 

Dactinomycin, actinomycin D

 

Rituxan (USA), MabThera (Europe)

Rituximab

IDEC-C2B8, RG105

Sprycel

Dasatinib

BMS-354825

Dacogen

Decitabine; dezocitidine

NSC-127716, DAC

Valstar, Valtaxin (Canada)

Valrubicin

AD32

Vantas

Histrelin

Formerly RL0903

Erwinase

Crisantaspase

 

Avastin

Bevacizumab

rhuMAb-VEGF, NSC-704865, R435, RG435

Gardasil, Silgard (Eastern Europe)

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

 

Velcade

Bortezomib

MLN341 (formerly LDP-341, PS-341 & MG-341)

Eligard (formerly Leuprogel)

Leuprolide acetate

SOT-375 (Japan)

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM